百特双向连接自动腹膜透析机HomeChoiceClaria获欧盟批准

2015年4月3日讯/生物谷BIOON/--百特（Baxter）研发的双向连接自动腹膜透析（APD）系统HomeChoiceClaria近日喜获欧盟批准。这款APD设备，配备了ShareSource双向连接网络平台，使临床医生能够远程监控患者的家庭护理，并根据处方进行相应的远程调整。
腹膜透析（PD）是一种可由患者在家中进行自助透析的治疗选择，主要用于末期肾脏病患者。
整合双向连接平台ShareSource的HomeChoiceClaria系统，可减少手动数据输入，同时使患者的维护记录能容易地访问，从而改善医疗保健人员的操作和时间效率。这款HomeChoiceClaria系统也提供了友好的用户界面，有41种语言可供设置，同时配备了一个大的显示器，可提供更佳的视觉感受。
HomeChoiceClaria是百特最畅销的首创APD设备HomeChoice的高级版本，后者上市已10多年，是唯一一款由泵驱动的循环透析设备。之后，百特推出了HomeChoicePro，这款腹膜透析机采用了一种特殊的临床软件和数据卡，采集每次透析的信息，使医生能够远程监控患者的治疗。
HomeChoiceClaria则配备了双向连接网络平台ShareSouce，通过一个网络连接系统，将医生和在家透析治疗的患者联系起来，能够实现更及时和更个性化的护理。
百特已计划在2015年首个季度将HomeChoiceClaria推向特定亚洲和欧洲国家。
英文原文：BaxterInternationalInc.GetsMarketingApprovalForLatestHomeDialysisDeviceInEurope
Baxtersharesroseinyesterday’stradingafterthecompanyannouncedmarketingapprovalforitslatestautomatedperitonealdialysisdeviceinEurope
BaxterInternationalInc.(NYSE:BAX)receivedmarketingapprovalinEuropeforitsautomatedperitonealdialysis(APD)systemcalledHOMECHOICECLARIA.TheAPDdevice,equippedwithSHARESOURCEweb-basedconnectivityplatform,offerstwo-wayconnectivitywhichensuresthatclinicianscaneasilymonitorthehome-basedperitonealdialysis(PD)therapyoftheirpatientsandmakeadjustmentstoprescriptionsaccordingly.
PDisahome-baseddialysistreatmentoptionavailablemainlytothosepatientswhoaregoingthroughthelaststageofrenaldisease.
HOMECHOICECLARIAintegratedwithSHARESOURCEwillalsohelptoimprovepracticeandtimeefficiencyofhealthcareprovidersbydecreasingmanualdataentryandmaintainingpatientrecordsthatcanbeeasilyaccessedbytheconcernedhealthcarestaff.TheHOMECHOICECLARIAdeviceisalsodesignedwithuser-friendlyinterfacewhichisaccessiblein41languagesandalargedisplayscreenwithtwo-linespaceforsharpvisibility.
CLARIAconstitutesanadvancedversionofBaxter’stop-selling,first-of-its-kindAPDdevicecalledHOMECHOICE,whichhasbeentheonlypump-basedcyclerfordialysispatientssincemorethanadecade.Thedeviceisportable,easy-to-use,andisdesignedtomeettheneedsofadultsandyoungrenalpatientsalike.
HOMECHOICEwassoonfollowedbyHOMECHOICEPROthatenableddoctorstoremotelymonitortheirpatients’treatmentwiththeuseofspecial,custom-basedclinicalsoftwareandadatacardwhichcapturedinformationfromeachdialysissession.
CLARIAbuildsupontheprevioustwoversionsofBaxter’sAPDsystemthroughintegrationofSHARESOUCE,whichconnectsdoctorsandhome-baseddialysispatientsthroughaweb-basedconnectivitysystem.
BruceCulleton,vicepresident,renaltherapeuticarealeadatBaxter,saidthattheCLARIAdevice“buildsuponourmarket-leadingHOMECHOICEAPDdevicewithnewfeaturestomakethesystemmoreintuitiveforpatientstooperateintheirhomeandwhiletraveling.”
HefurtheraddedthattheSHARESOURCEsystemdistinguishesCLARIAfromthepriorversionsofHOMECHOICEbyproviding“physiciansremoteaccesstotheirhomepatientstreatmentinformationallowingformoretimelyandpersonalizedcare.”
BaxterexpectstobeginlaunchoftheHOMECHOICECLARIAdevicebythefirsthalfof2015incertainAsianandEuropeancountries.
JillSchaaf,presidentofBaxtersrenalbusiness,highlightedthecompany’scommitmenttoincreasinglifeexpectancyandqualityoflifeforrenalpatients,saying:"Everypatientwithend-stagerenaldiseasedeservesaccesstoindividualizedcare.HOMECHOICECLARIAwithSHARESOURCErepresentsBaxterscontinuedcommitmenttoadvancingrenaltechnologythatoffershealthcareprovidersandpatientstherapyoptionsforend-stagerenaldisease."
TheannouncementofCEmarking(approvalformarketlaunchinEurope)completionforHOMCHOICECLARIAcausedthesharepriceofBaxtertoreachthehighestpointat$68.31apieceinyesterday’stradingsession,upfrom$68.20pershare.Baxterstockclosedat$67.54pershareyesterday.
医药网新闻